Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
ALIOF's Cash-to-Debt is ranked higher than
89% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. ALIOF: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ALIOF' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.3  Med: 4 Max: No Debt
Current: No Debt
Equity-to-Asset 0.69
ALIOF's Equity-to-Asset is ranked higher than
51% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ALIOF: 0.69 )
Ranked among companies with meaningful Equity-to-Asset only.
ALIOF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.62 Max: 0.72
Current: 0.69
0.5
0.72
Interest Coverage 158967.40
ALIOF's Interest Coverage is ranked higher than
100% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALIOF: 158967.40 )
Ranked among companies with meaningful Interest Coverage only.
ALIOF' s Interest Coverage Range Over the Past 10 Years
Min: 0.3  Med: 57.05 Max: 158967.4
Current: 158967.4
0.3
158967.4
Piotroski F-Score: 8
Altman Z-Score: 27.25
Beneish M-Score: -2.88
WACC vs ROIC
7.06%
79.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 32.12
ALIOF's Operating Margin % is ranked higher than
94% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. ALIOF: 32.12 )
Ranked among companies with meaningful Operating Margin % only.
ALIOF' s Operating Margin % Range Over the Past 10 Years
Min: 0.68  Med: 24.79 Max: 32.62
Current: 32.12
0.68
32.62
Net Margin % 28.89
ALIOF's Net Margin % is ranked higher than
93% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. ALIOF: 28.89 )
Ranked among companies with meaningful Net Margin % only.
ALIOF' s Net Margin % Range Over the Past 10 Years
Min: -8.15  Med: 20.51 Max: 30.33
Current: 28.89
-8.15
30.33
ROE % 50.89
ALIOF's ROE % is ranked higher than
98% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. ALIOF: 50.89 )
Ranked among companies with meaningful ROE % only.
ALIOF' s ROE % Range Over the Past 10 Years
Min: -8.85  Med: 27.86 Max: 52.69
Current: 50.89
-8.85
52.69
ROA % 34.22
ALIOF's ROA % is ranked higher than
98% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. ALIOF: 34.22 )
Ranked among companies with meaningful ROA % only.
ALIOF' s ROA % Range Over the Past 10 Years
Min: -5.18  Med: 14.9 Max: 34.63
Current: 34.22
-5.18
34.63
ROC (Joel Greenblatt) % 156.43
ALIOF's ROC (Joel Greenblatt) % is ranked higher than
95% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. ALIOF: 156.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALIOF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5.55  Med: 117.89 Max: 163.6
Current: 156.43
-5.55
163.6
3-Year Revenue Growth Rate 13.20
ALIOF's 3-Year Revenue Growth Rate is ranked higher than
66% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ALIOF: 13.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALIOF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -0.9  Med: 10.7 Max: 134.5
Current: 13.2
-0.9
134.5
3-Year EBITDA Growth Rate 19.20
ALIOF's 3-Year EBITDA Growth Rate is ranked higher than
71% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. ALIOF: 19.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALIOF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -48.4  Med: 28.5 Max: 133.9
Current: 19.2
-48.4
133.9
3-Year EPS without NRI Growth Rate 18.10
ALIOF's 3-Year EPS without NRI Growth Rate is ranked higher than
72% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. ALIOF: 18.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALIOF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0.5  Med: 35.9 Max: 123.5
Current: 18.1
0.5
123.5
GuruFocus has detected 3 Warning Signs with Actelion Ltd $ALIOF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALIOF's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ALIOF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 2833
Compare:XSWX:BION, XSWX:GALE, XSWX:IDIA, XSWX:SFZN, XSWX:BSLN, XSWX:HBMNE, NAS:CRSP, NAS:ACIU, XSWX:MOLN, XSWX:SANN, NAS:OBSV, XSWX:EVE, XSWX:KURN, XPAR:GNRO, XSWX:ADXN, NAS:EARS, OTCPK:MYMX, XSWX:RLF » details
Traded in other countries:ACT.Germany, ATLNE.Switzerland, 0RN5.UK,
Headquarter Location:Switzerland
Actelion Ltd is a Swiss biopharmaceutical firm. It is engaged in the discovery, development and commercialization of drugs for diseases with unmet medical needs.

Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Top Ranked Articles about Actelion Ltd

Johnson & Johnson Announces Expected Settlement of Actelion Tender Offer on June 16, 2017
Johnson & Johnson Beats on Profit, Misses on Sales in 1st Quarter Shares were down in early afternoon trading
Health care giant Johnson & Johnson (NYSE:JNJ) posted sluggish sales for the first quarter of the year, offsetting an increase in profit. Sales were squeezed by pressure to reduce drug prices and a global decline in sales of health products. Read more...
Johnson & Johnson Publishes Interim Result for Actelion Tender Offer and Declares the Tender Offer Successful

Ratios

vs
industry
vs
history
PE Ratio 40.12
ALIOF's PE Ratio is ranked lower than
61% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. ALIOF: 40.12 )
Ranked among companies with meaningful PE Ratio only.
ALIOF' s PE Ratio Range Over the Past 10 Years
Min: 11.02  Med: 20.63 Max: 42.66
Current: 40.12
11.02
42.66
PE Ratio without NRI 40.12
ALIOF's PE Ratio without NRI is ranked lower than
60% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. ALIOF: 40.12 )
Ranked among companies with meaningful PE Ratio without NRI only.
ALIOF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.02  Med: 20.63 Max: 42.66
Current: 40.12
11.02
42.66
Price-to-Owner-Earnings 34.49
ALIOF's Price-to-Owner-Earnings is ranked higher than
50% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. ALIOF: 34.49 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ALIOF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.72  Med: 25.17 Max: 2686.36
Current: 34.49
12.72
2686.36
PB Ratio 17.39
ALIOF's PB Ratio is ranked lower than
90% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. ALIOF: 17.39 )
Ranked among companies with meaningful PB Ratio only.
ALIOF' s PB Ratio Range Over the Past 10 Years
Min: 2.35  Med: 4.98 Max: 21.19
Current: 17.39
2.35
21.19
PS Ratio 11.60
ALIOF's PS Ratio is ranked higher than
51% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. ALIOF: 11.60 )
Ranked among companies with meaningful PS Ratio only.
ALIOF' s PS Ratio Range Over the Past 10 Years
Min: 1.96  Med: 5.32 Max: 12.33
Current: 11.6
1.96
12.33
Price-to-Free-Cash-Flow 32.30
ALIOF's Price-to-Free-Cash-Flow is ranked lower than
58% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. ALIOF: 32.30 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALIOF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.64  Med: 24.1 Max: 187.42
Current: 32.3
8.64
187.42
Price-to-Operating-Cash-Flow 30.25
ALIOF's Price-to-Operating-Cash-Flow is ranked lower than
58% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. ALIOF: 30.25 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALIOF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.44  Med: 20.23 Max: 137.53
Current: 30.25
8.44
137.53
EV-to-EBIT 34.33
ALIOF's EV-to-EBIT is ranked lower than
65% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. ALIOF: 34.33 )
Ranked among companies with meaningful EV-to-EBIT only.
ALIOF' s EV-to-EBIT Range Over the Past 10 Years
Min: -108.9  Med: 18.4 Max: 37.1
Current: 34.33
-108.9
37.1
EV-to-EBITDA 30.90
ALIOF's EV-to-EBITDA is ranked lower than
67% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. ALIOF: 30.90 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALIOF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -77.3  Med: 17.4 Max: 206.8
Current: 30.9
-77.3
206.8
EV-to-Revenue 11.02
ALIOF's EV-to-Revenue is ranked higher than
54% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. ALIOF: 11.02 )
Ranked among companies with meaningful EV-to-Revenue only.
ALIOF' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.4  Med: 5 Max: 11.9
Current: 11.02
1.4
11.9
PEG Ratio 0.69
ALIOF's PEG Ratio is ranked higher than
83% of the 102 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. ALIOF: 0.69 )
Ranked among companies with meaningful PEG Ratio only.
ALIOF' s PEG Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.34
Current: 0.69
0
1.34
Current Ratio 2.76
ALIOF's Current Ratio is ranked lower than
63% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ALIOF: 2.76 )
Ranked among companies with meaningful Current Ratio only.
ALIOF' s Current Ratio Range Over the Past 10 Years
Min: 1.41  Med: 2.28 Max: 3.95
Current: 2.76
1.41
3.95
Quick Ratio 2.51
ALIOF's Quick Ratio is ranked lower than
62% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. ALIOF: 2.51 )
Ranked among companies with meaningful Quick Ratio only.
ALIOF' s Quick Ratio Range Over the Past 10 Years
Min: 1.36  Med: 2.19 Max: 3.8
Current: 2.51
1.36
3.8
Days Inventory 169.01
ALIOF's Days Inventory is ranked lower than
62% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. ALIOF: 169.01 )
Ranked among companies with meaningful Days Inventory only.
ALIOF' s Days Inventory Range Over the Past 10 Years
Min: 88.91  Med: 106.4 Max: 169.01
Current: 169.01
88.91
169.01

Buy Back

vs
industry
vs
history
Dividend Payout Ratio 0.22
ALIOF's Dividend Payout Ratio is ranked higher than
69% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. ALIOF: 0.22 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ALIOF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0  Med: 0.26 Max: 0.31
Current: 0.22
0
0.31
3-Year Dividend Growth Rate 14.50
ALIOF's 3-Year Dividend Growth Rate is ranked higher than
64% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. ALIOF: 14.50 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ALIOF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 17.6
Current: 14.5
0
17.6
5-Year Yield-on-Cost % 1.09
ALIOF's 5-Year Yield-on-Cost % is ranked lower than
61% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. ALIOF: 1.09 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ALIOF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.05  Med: 2.25 Max: 5.34
Current: 1.09
1.05
5.34
3-Year Average Share Buyback Ratio 2.50
ALIOF's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. ALIOF: 2.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALIOF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: 0  Med: 2.4 Max: 42
Current: 2.5
0
42

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 770.19
ALIOF's Price-to-Net-Cash is ranked lower than
99% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. ALIOF: 770.19 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ALIOF' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 11.79  Med: 33.27 Max: 807.71
Current: 770.19
11.79
807.71
Price-to-Net-Current-Asset-Value 38.83
ALIOF's Price-to-Net-Current-Asset-Value is ranked lower than
92% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. ALIOF: 38.83 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALIOF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.58  Med: 13.54 Max: 55.26
Current: 38.83
4.58
55.26
Price-to-Tangible-Book 25.30
ALIOF's Price-to-Tangible-Book is ranked lower than
92% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ALIOF: 25.30 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALIOF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.98  Med: 7.63 Max: 28.15
Current: 25.3
2.98
28.15
Price-to-Intrinsic-Value-Projected-FCF 3.93
ALIOF's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
55% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. ALIOF: 3.93 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALIOF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.84  Med: 2.94 Max: 4.14
Current: 3.93
1.84
4.14
Price-to-Median-PS-Value 2.18
ALIOF's Price-to-Median-PS-Value is ranked lower than
85% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ALIOF: 2.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALIOF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 1.01 Max: 2.91
Current: 2.18
0.38
2.91
Price-to-Graham-Number 6.72
ALIOF's Price-to-Graham-Number is ranked lower than
81% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. ALIOF: 6.72 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ALIOF' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.41  Med: 2.73 Max: 7.09
Current: 6.72
1.41
7.09
Earnings Yield (Greenblatt) % 2.91
ALIOF's Earnings Yield (Greenblatt) % is ranked higher than
83% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. ALIOF: 2.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALIOF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4.2  Med: 4.8 Max: 12.1
Current: 2.91
-4.2
12.1

More Statistics

Revenue (TTM) (Mil) $2,497.16
EPS (TTM) $ 6.77
Beta1.73
Short Percentage of Float0.00%
52-Week Range $138.01 - 286.30
Shares Outstanding (Mil)104.64

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2,456 2,589 2,692
EPS ($) 8.14 6.79 7.10
EPS without NRI ($) 8.14 6.79 7.10
EPS Growth Rate
(Future 3Y To 5Y Estimate)
13.37%
Dividends per Share ($) 1.55
» More Articles for ALIOF

Headlines

Articles On GuruFocus.com
Johnson & Johnson Announces Expected Settlement of Actelion Tender Offer on June 16, 2017 Jun 09 2017 
Johnson & Johnson: Modest Price Decline Presents Buying Opportunity Apr 21 2017 
Johnson & Johnson Beats on Profit, Misses on Sales in 1st Quarter Apr 19 2017 
Johnson & Johnson Publishes Interim Result for Actelion Tender Offer and Declares the Tender Offer S Mar 31 2017 
Health Care Dividend Stock Showdown Mar 03 2017 
Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary Feb 14 2017 
Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary Jan 24 2017 
Jean Hynes Reduces Stake in Actelion Aug 03 2016 
Actelion Still On Growth Track Feb 18 2015 

More From Other Websites
Actelion Ltd. breached its 50 day moving average in a Bullish Manner : ALIOF-US : September 19, 2017 Sep 19 2017
The Smartest Move Johnson & Johnson Has Made All Year Sep 15 2017
J&J (JNJ) PAH Drug's U.S. Label Expanded for Pediatric Use Sep 07 2017
Actelion Ltd. breached its 50 day moving average in a Bearish Manner : ALIOF-US : August 28, 2017 Aug 28 2017
Actelion Ltd. – Value Analysis (US OTC:ALIOF) : August 24, 2017 Aug 24 2017
Johnson & Johnson Shares Might Break Lower Before They Break Out Jul 21 2017
Johnson & Johnson Shares Strong Since Actelion Acquisition, But Potential For Upside Remains Jul 20 2017
J&J sees sales growth in near-term; raises 2017 profit forecast Jul 18 2017
4 Things That Matter When Johnson & Johnson Reports Its Second-Quarter Results Jul 17 2017
ETFs with exposure to Actelion Ltd. : July 13, 2017 Jul 13 2017
J&J CEO Gorsky on M&A, Health Care, Tax Reform Jun 26 2017
ETFs with exposure to Actelion Ltd. : June 19, 2017 Jun 19 2017
Actelion Ltd. :ALIOF-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Jun 16 2017
Actelion spin-off Idorsia's shares rise 30 pct in market debut Jun 16 2017
Actelion spin-off Idorsia makes market debut at 10 Sfr per share Jun 16 2017
Actelion Ltd. breached its 50 day moving average in a Bearish Manner : ALIOF-US : June 15, 2017 Jun 15 2017
J&J Announces EU Regulatory Approval for Actelion Deal Jun 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}